{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:43:25Z","timestamp":1792813405871,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Intramural Research Program of the NIH, Clinical Center and National Cancer Institute"},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Harper Fund"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jcyt.2016.04.003","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:53:20Z","timestamp":1463446400000},"page":"893-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"title":["Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells"],"prefix":"10.1016","volume":"18","author":[{"given":"David F.","family":"Stroncek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ellen","family":"Frodigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh","family":"Khuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda S.","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2016.04.003_bib0010","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0015","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0020","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0035","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0040","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0045","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0050","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","article-title":"Simplified process for the production of anti-CD19-CAR-engineered T cells","volume":"15","author":"Tumaini","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0055","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2013.1.348","article-title":"T-cell adoptive immunotherapy for acute lymphoblastic leukemia","volume":"2013","author":"Fry","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0060","first-page":"349","article-title":"Myeloid-derived suppressor cells as therapeutic target in hematological malignancies","volume":"4","author":"De","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0065","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1007\/s13277-015-4004-z","article-title":"Myeloid-derived suppressor cells in B cell malignancies","volume":"36","author":"Yazdani","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0070","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.humimm.2014.09.025","article-title":"Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients","volume":"75","author":"Jiang","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0075","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood-2012-08-449413","article-title":"Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/nyas.12469","article-title":"Myeloid-derived suppressor cell heterogeneity in human cancers","volume":"1319","author":"Solito","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12967-014-0241-y","article-title":"Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies","volume":"12","author":"Stroncek","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0090","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3109\/14653240903188921","article-title":"Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program","volume":"11","author":"Powell","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0095","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-15-0340","article-title":"High-dose sirolimus and immune-selective pentostatin plus cyclophosphamide conditioning yields stable mixed chimerism and insufficient graft-versus-tumor responses","volume":"21","author":"Mossoba","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1479-5876-10-29","article-title":"Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry","volume":"10","author":"Zheng","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2016.04.003_bib0110","doi-asserted-by":"crossref","first-page":"e57838","DOI":"10.1371\/journal.pone.0057838","article-title":"Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials","volume":"8","author":"Jena","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324916303450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324916303450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:23:30Z","timestamp":1761431010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324916303450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1465324916303450"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2016.04.003","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2016.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society for Cellular Therapy.","name":"copyright","label":"Copyright"}]}}